Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 5, 2014-06 ,pp. : 646-650

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

By Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1299-1304

Springer Publishing Company

Access to resources Recommend Favorite

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

By Casal Rubio J.   Fírvida-Pérez J.   Lázaro-Quintela M.   Barón-Duarte F.   Alonso-Jáudenes G.   Santomé L.   Afonso-Afonso F.   Amenedo M.   Huidobro G.   Campos-Balea B.   López-Vázquez M.   Vázquez S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 451-457

Springer Publishing Company

Access to resources Recommend Favorite

Erlotinib in the first-line treatment of non-small-cell lung cancer

By D'Arcangelo Manolo   Cappuzzo Federico  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 523-533

Informa Healthcare

Access to resources Recommend Favorite

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients

By Santarpia Mariacarmela   De Pas Tommaso Martino   Altavilla Giuseppe   Spaggiari Lorenzo   Rosell Rafael  

Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. : 327-345

Future Medicine

Access to resources Recommend Favorite